China NMPA Clarifies Pre-Review for Innovative Device Clinical Trials

On March 13, 2026, China’s National Medical Products Administration (NMPA) Center for Medical Device Evaluation (CMDE) issued the notice “Notice on Matters Related to the Pre-Review of Clinical Trial Protocols for Innovative Medical Devices,” clarifying procedural and technical requirements for pre-review of clinical trial protocols for innovative medical devices.

For foreign manufacturers, this update raises expectations for early-stage data readiness and reinforces the need for structured, proactive regulatory engagement when pursuing innovative device approval in China.

Refines Clinical Trial Protocol Pre-Review Pathway

This notice builds on the broader reform framework outlined in “Opinions on Deepening the Reform of Drug and Medical Device Regulation to Promote High-Quality Development of the Pharmaceutical Industry” and reflects ongoing efforts to streamline China’s innovation pathway.

The NMPA confirms that applicants must submit pre-review requests through the established “major technical issue communication pathway” for innovative products. Each submission must clearly state that it is a clinical trial protocol pre-review request.

For international manufacturers, this reinforces the structured and centralized nature of China’s innovation pathway — particularly for devices seeking priority consideration.

Clearer Data and Submission Expectations for Applicants

The notice introduces more explicit expectations on the quality and completeness of supporting data submitted for pre-review.

Required Supporting Documentation

Applicants must provide comprehensive materials, including:

• A rationale for the clinical study
• Relevant non-clinical research data
• A fully developed clinical trial protocol
• Supporting evidence describing product characteristics, mechanism of action, and risk profile

The NMPA emphasizes that protocols must be scientifically justified and based on sufficient prior research, including feasibility studies where applicable.

Focus on Risk and Product Characterization

Submissions must clearly demonstrate:

• Intended use and clinical application scope
• Key functional and performance parameters
• Acceptable clinical risk based on existing evidence

This reflects a continued shift toward risk-based evaluation and more rigorous early-stage scrutiny, therefore aligning China more closely with international regulatory expectations.

More Structured Review and Feedback Mechanisms

The notice also clarifies how the CMDE will handle incomplete or insufficient submissions and how feedback will be delivered.

If materials do not meet requirements, the agency may provide feedback, including via video meetings, and require resubmission. If acceptable, the pre-review may include expert consultation meetings, where applicants must present detailed technical and clinical design information.

Importantly, the resulting pre-review opinions are explicitly defined as non-binding guidance, not formal regulatory conclusions.

Implications for International Medical Device Companies

This update provides greater procedural clarity but does not fundamentally change regulatory thresholds.

For overseas manufacturers, key takeaways include:

• Earlier and more robust preparation of clinical and non-clinical data is essential
• Pre-review is becoming a more formalized gatekeeping step in China’s innovation pathway
• Engagement with the CMDE is increasingly structured, with defined communication channels and expectations

Companies should also note that significant post-pre-review product changes may trigger the need for a new pre-review submission.

Final Thoughts: How This Update Affects Innovation Pathways in China

This is not a major policy shift, but it is operationally important. The notice enhances transparency, reduces ambiguity in submission expectations, and signals continued maturation of China’s regulatory system for innovative devices.

For international companies, the key consideration is earlier alignment. The NMPA is placing greater emphasis on well-prepared clinical and non-clinical data, alongside more structured engagement through the pre-review pathway.

As a result, integrating regulatory strategy earlier into clinical development will be critical to maintaining timelines. With the right preparation, companies can navigate pre-review more efficiently and reduce delays. Cisema supports this process — from strengthening submission readiness to facilitating effective engagement with the CMDE — helping international manufacturers move more smoothly through China’s innovation pathway.

For support with China medical device registration and clinical trial strategy, contact Cisema today.

Further Information

Explore Cisema’s services for medical device registration and compliance in China.

References

Notice on Matters Related to the Pre-Review of Clinical Trial Protocols for Innovative Medical Devices